


Supplementary Figure S2



Patients who last received aCD20 >1y prior to vaccination




Figure S2. (A) Blocking antibody responses among patients who have ever received anti-CD20 antibody treatment by time since date of last anti-CD20 antibody treatment. **(B-G)** Characteristics of “blocking-negative” and “blocking-positive” patients among those who had last received an anti-CD20-targeting antibody more than 1 year prior to vaccination: age (B), sex (C), vaccine type (D), prior receipt of chemotherapy (E), lymphoma subtype (F), and disease status (G). aCD20, anti-CD20 antibody. FL, follicular lymphoma, DLBCL, diffuse large B cell lymphoma. MZL, marginal zone lymphoma. LYPCL, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. HGBCL/Burkitt, high grade B cell lymphoma/Burkitt lymphoma.